Researchers analyzed data from 1,903 patients with stage 3 or stage 4 epithelial ovarian cancer who were enrolled in four ...

Researchers have resolved a 50-year-old scientific mystery by identifying the molecular mechanism that allows tissues to ...

Researchers at Åbo Akademi University have identified a new molecular change in patients with colorectal cancer and developed ...

Deep in the folds of the intestine, in microscopic pockets called crypts, a quiet surveillance system is always at work. Stem ...

A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.